证券代码：688076 证券简称：ST 诺泰 公告编号：2025-059 江苏诺泰澳赛诺生物制药股份有限公司 关于自愿披露注射用醋酸西曲瑞克、阿戈美拉汀片获 得药品注册证书的公告 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"或"诺泰生物"） 于近日收到国家药品监督管理局核准签发的注射用醋酸西曲瑞克、阿戈美拉汀片 的《药品注册证书》（证书编号：2025S02223、2025S02377），现将相关情况 公告如下： 一、《药品注册证书》的主要内容 1、药品名称：注射用醋酸西曲瑞克 剂型：注射剂 规格：0.25mg（按 C70H92C1N17O14计） 申请事项：药品注册（境内生产） 注册分类：化学药品 4 类 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 药品有效期：18 个月 包装规格：每盒 7 瓶，每盒 1 瓶 上市许可持有人：江苏诺泰澳赛诺生物制药股份有限公司 生产企业：江苏诺泰澳赛诺生物制药股份有限公司 药品批准文号：国药准字 H20254895 药品批准文号有效期：至 2030 年 7 月 21 日 审批结论 ...

Group 1 - The core viewpoint of the article highlights the significant changes and developments in the Sci-Tech Innovation Board (STAR Market) since its inception, emphasizing its role in optimizing the A-share market structure and supporting key technological advancements in China [1] - As of July 22, 2025, a total of 591 companies have been listed on the STAR Market, with a cumulative IPO fundraising amount of 927.156 billion yuan and a total market capitalization exceeding 7 trillion yuan [1] - The STAR Market has become an important platform for tackling key core technologies under a new type of national system [1] Group 2 - In the past six years, the leading underwriters for IPOs on the STAR Market include Guotai Junan and Haitong Securities, with a combined total of 213.777 billion yuan raised from 112 underwriting cases [2][5] - CITIC Securities follows with 167.069 billion yuan from 99 cases, while China International Capital Corporation (CICC) and CITIC Jianzhong Securities rank third and fourth, respectively, in terms of underwriting volume [5] - The overall low rate of serious issues among listed companies is noted, with only 7 out of 591 companies facing significant problems, resulting in a low incidence rate of 1.18% [5][6] Group 3 - Nanjing Securities has faced scrutiny due to its involvement with ST Nuotai, which was flagged for financial misconduct shortly after its IPO, raising concerns about the quality of its ongoing supervision [7][9] - The company earned 211 million yuan in underwriting fees from three IPO projects, with ST Nuotai being a significant contributor despite its subsequent financial issues [7][8] - The regulatory body has not penalized Nanjing Securities for its oversight failures, despite the serious nature of the financial discrepancies found in ST Nuotai's reports [9][12]

Core Viewpoint - Notai Bio (688076.SH) has been penalized for financial fraud, leading to a downgrade in valuation by fund companies after being designated as ST (Special Treatment) following its resumption of trading [2][7]. Group 1: Financial Fraud and Penalties - The China Securities Regulatory Commission (CSRC) confirmed that Notai Bio's 2021 annual report contained false records, resulting in a total fine of 76.2 million yuan for the company and several executives [2][6]. - Notai Bio's fraudulent activities included inflating revenue by 30 million yuan and profit by 25.95 million yuan, which accounted for 20.64% of the reported total profit for that year [4][5]. - The company was also penalized for providing misleading financial information in its bond issuance documents, leading to additional fines totaling 47.4 million yuan [5][6]. Group 2: Market Impact and Fund Valuation Adjustments - Following the ST designation, Notai Bio's stock closed at 44.51 yuan per share, with a total market capitalization of 14.07 billion yuan [3]. - On July 22, 2025, the valuation of Notai Bio's stock was adjusted to 32.78 yuan by the招商基金, reflecting a reduction of approximately 20% from its previous price of 40.98 yuan [8][9]. - As of the end of Q2 2025, 19 funds from 8 public fund companies held a total of 9.23 million shares of Notai Bio, with a combined market value of 344 million yuan, representing 2.93% of the total share capital [10].

Core Viewpoint - The stock of NuoTai Bio (688076.SH) was officially changed to "ST NuoTai" following the announcement of a financial fraud case, leading to an 11% drop in stock price on the first trading day after the change [1][2]. Group 1: Financial Fraud Details - NuoTai Bio's financial fraud was revealed in the "Administrative Penalty Notice" issued by the China Securities Regulatory Commission (CSRC), indicating that the company had fabricated financial data in its 2021 annual report [2][3]. - The fraudulent activity involved a technology transfer to Zhejiang Huabei Pharmaceutical Co., which lacked the financial capability and operational capacity to pay for or utilize the technology, resulting in an inflated revenue of 30 million yuan and an inflated profit of 25.9516 million yuan, accounting for 20.64% of the reported profit [3][4]. - NuoTai Bio also included false financial data in its convertible bond issuance documents, continuing to use the fraudulent 2021 financial figures in its fundraising materials [3]. Group 2: Penalties and Consequences - The CSRC proposed penalties against NuoTai Bio, including a fine of 47.4 million yuan and warnings for the company and its executives, with total penalties amounting to 76.2 million yuan, setting a record for penalties on the STAR Market [4][5]. - The actual controllers of NuoTai Bio, Zhao Dezhong and Zhao Deyi, received fines of 13 million yuan and 5 million yuan respectively, while four senior executives were fined between 1.5 million and 3.3 million yuan [4][5]. Group 3: Role of Nanjing Securities - Nanjing Securities, the sponsor for NuoTai Bio's IPO and convertible bond issuance, is implicated in the fraud due to its confirmation of the accuracy of the financial disclosures in the listing and bond issuance documents [6]. - Nanjing Securities earned approximately 66.3854 million yuan in underwriting fees from the IPO and around 5.66 million yuan from the convertible bond project [6]. - The firm has faced multiple issues with its sponsored projects, including instances of financial fraud and information disclosure violations [7][8].

Core Viewpoint - The company NuoTai Bio (688076.SH) has been penalized by the China Securities Regulatory Commission (CSRC) for financial fraud and has officially been designated as ST (Special Treatment) due to its violations, which include fabricating financial data and misleading disclosures [1][3]. Group 1: Company Violations - NuoTai Bio was found to have falsely recognized 30 million yuan in revenue through fictitious technology transfers, inflating profits by 25.95 million yuan, which accounted for 20.6% of the disclosed amount [1]. - The company also fabricated significant content in its public offering documents, with the 2023 convertible bond prospectus continuing to use this false data, constituting a serious violation of issuance document integrity [1][3]. Group 2: Underwriter's Responsibility - Nanjing Securities (601990.SH), as the underwriter for NuoTai Bio, was deeply involved in its financing operations and failed to identify the discrepancies in the financial disclosures, despite confirming the accuracy of the information provided [3][6]. - The underwriter received a total of 66.3854 million yuan in underwriting fees for the IPO and an additional 5.66 million yuan for the convertible bond project, raising questions about its due diligence practices [3][6]. Group 3: Regulatory and Market Impact - Following the scandal, Nanjing Securities has faced scrutiny for its oversight quality, with over 40% of the 17 IPO and refinancing companies it has supervised in the past decade encountering issues such as financial fraud and disclosure violations [6]. - Despite achieving a record net profit of 1 billion yuan in 2024, Nanjing Securities reported an 11.6% decline in revenue in the first quarter of 2025, indicating potential weaknesses in its business performance [7]. Group 4: Future Outlook - NuoTai Bio's stock will be subject to additional risk warnings from the Shanghai Stock Exchange, but it does not currently face mandatory delisting due to major legal violations [8]. - Nanjing Securities' 5 billion yuan private placement plan has faced delays and scrutiny, with the validity of the plan extended to July 2026, leaving its future uncertain [8].

Core Viewpoint - The article reveals the fraudulent activities of Nuotai Bio, a company involved in the weight-loss drug sector, which led to its stock suspension and significant penalties from regulatory authorities [1][2]. Group 1: Fraudulent Activities - Nuotai Bio was found to have fabricated transactions in its first year of listing, resulting in a fraudulent issuance of convertible bonds amounting to 434 million yuan [1]. - The company engaged in a scheme where it transferred drug technology to a shell company, Zhejiang Huabei, falsely recognizing revenue of 30 million yuan, while the shell company had no payment capability or production technology [1]. - This "self-financing" scheme inflated Nuotai's profits by 25.95 million yuan, accounting for 20.64% of its total profit for that year [1]. Group 2: Regulatory Actions and Consequences - The China Securities Regulatory Commission (CSRC) imposed a total fine of 76.2 million yuan on Nuotai Bio, including 4 million yuan for false annual report records and 43.4 million yuan for fraudulent issuance [1][2]. - The actual controller, Zhao Dezhong, was fined 18 million yuan, and several executives faced penalties exceeding 10 million yuan collectively [1]. Group 3: Market Impact and Future Outlook - Despite the severity of the fraud, Nuotai Bio did not meet the criteria for mandatory delisting under the new 2024 regulations, as its inflated profits were below the 200 million yuan threshold [2]. - The company will face a prolonged period of risk warning trading, as it must restate its financial reports and wait at least one year to apply for removal of the warning [2]. - The scandal serves as a warning for the booming pharmaceutical outsourcing industry, highlighting the need for vigilance against financial bubbles amid rising capital interest in GLP-1 weight-loss drugs [2].

Core Viewpoint - ST诺泰 (688076.SH) has received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) due to violations related to information disclosure and financial misstatements in its 2021 annual report, leading to significant penalties for the company and its executives [1][5][6]. Group 1: Violations and Penalties - ST诺泰's 2021 annual report falsely recorded revenue of 30 million yuan and inflated total profit by 25.95 million yuan, accounting for 20.64% of the reported profit for that period [1][5]. - The CSRC has proposed a total penalty of 47.4 million yuan for ST诺泰, including 4 million yuan for the company and additional fines for its executives, with the actual controller Zhao Dezhong facing a total of 1.3 million yuan in penalties [6][7]. - The company and its executives are accused of fabricating significant false content in public offering documents, violating multiple regulations under the Securities Law [5][6]. Group 2: Management Involvement - Zhao Dezhong, the actual controller, and other key executives, including Zhao Deyi and Jin Fuqiang, were directly responsible for the violations and signed off on the misleading financial reports [2][5][6]. - The management's failure to address the irregularities in the financial statements and public offering documents has been highlighted, indicating a lack of oversight [2][4]. Group 3: Financial Impact - The inflated revenue and profit figures significantly misrepresented the company's financial health, which could impact investor trust and stock performance [1][5]. - Following the announcement of penalties, ST诺泰's stock was subjected to risk warnings and a name change to ST诺泰, reflecting its troubled status [7]. Group 4: Fund Holdings and Market Reaction - As of mid-2025, various funds, including those managed by 招商基金, hold significant shares in ST诺泰, with a total of 923.38 million shares held by multiple funds [10][11]. - Following the penalties, 招商基金 adjusted the valuation of its holdings in ST诺泰, indicating a market reaction to the company's financial issues [11].

Core Viewpoint - The article highlights the severe penalties imposed on Nuotai Bio for financial misconduct, including false reporting in its 2021 annual report and significant inaccuracies in its public offering documents, reflecting serious internal governance issues [1][4][8]. Financial Penalties and Market Reaction - Nuotai Bio was fined 47.4 million yuan and its actual controller, Zhao Dezhong, was fined 13 million yuan due to violations in financial reporting [1][2]. - Following the announcement, the stock price dropped over 11% upon resuming trading, closing at 39.22 yuan per share, a decline of 4.29% from the last trading day before suspension [2]. Internal Governance Issues - The financial discrepancies stemmed from a questionable technology transfer deal with Zhejiang Huabei, which was not a legitimate transaction, leading to inflated revenue and profit figures in the 2021 annual report [5][6]. - The internal management flaws have been previously noted, with past regulatory warnings indicating ongoing issues with governance and compliance [7][8]. Business Performance and Growth - Despite the recent controversies, Nuotai Bio has shown significant growth in revenue, increasing from 371 million yuan in 2019 to 1.625 billion yuan in 2024, with a net profit rise from 49 million yuan to 404 million yuan [10][11]. - The company has established strategic partnerships in the GLP-1 drug sector, contributing to its revenue growth and positioning in the market [11][12]. Industry Context and Future Outlook - The demand for peptide drugs is surging, with Nuotai Bio positioned to benefit from this trend, although concerns about overcapacity in the peptide sector exist [12][13]. - The company faces a dual challenge of capitalizing on market opportunities while addressing internal governance issues that could undermine investor confidence [13].

Core Viewpoint - The company, 诺泰生物, faced regulatory actions due to financial fraud, leading to a temporary suspension of its stock and subsequent risk warnings from the China Securities Regulatory Commission (CSRC) [1][4]. Financial Misconduct - 诺泰生物 inflated its operating income by 30 million yuan and its total profit by 25.9516 million yuan in its 2021 annual report, which accounted for 20.64% of the disclosed profit for that period [3]. - The fraudulent activities involved a technology transfer to 浙江华贝药业, which lacked the financial capability to pay for the technology and did not possess the necessary production and sales capabilities [3]. Regulatory Actions - The CSRC plans to impose a fine of 47.4 million yuan on 诺泰生物 and issue warnings, with penalties also directed at the actual controller, 赵德中, totaling 13 million yuan [4]. - The company and six senior executives face a total penalty of 76.2 million yuan due to their involvement in the fraudulent activities [4]. Fund Holdings - Several public funds, including 招商基金, hold significant stakes in 诺泰生物, with a combined market value exceeding 340 million yuan as of mid-year [3]. - 招商基金's products collectively hold 7.3306 million shares, representing 2.46% of the circulating A-shares of 诺泰生物 [3].

Core Viewpoint - The financial fraud case of Nuotai Bio (688076.SH) has been exposed, leading to its being designated as ST (Special Treatment) after resuming trading on July 22. The China Securities Regulatory Commission (CSRC) has issued a notice of administrative penalty, confirming that the company fabricated operating income and profits in 2021 [1][3][5]. Financial Fraud Details - In 2021, Nuotai Bio falsely reported operating income of 30 million yuan and inflated total profits by 25.9516 million yuan, which accounted for 20.64% of the reported profit for that year [4][5]. - The fraudulent activities involved a technical transfer to Zhejiang Huabei Pharmaceutical Co., which lacked the financial capability and operational capacity to utilize the technology, indicating that the transaction had no commercial substance [4][5]. Regulatory Actions - The CSRC plans to impose a fine of 47.4 million yuan on Nuotai Bio and a total of 18 million yuan on its actual controllers, Zhao Dezhong and Zhao Deyi [1][5][6]. - The company received a notice of investigation from the CSRC on October 22, 2024, regarding violations of information disclosure and fraudulent issuance [3][5]. Financial Condition - As of the first quarter of 2025, Nuotai Bio's debt-to-asset ratio reached 47.76%, a significant increase from less than 15% at the end of 2021, indicating financial pressure [2]. - The company reported net profits of 129 million yuan, 163 million yuan, and 404 million yuan for the years 2022 to 2024, with a substantial growth rate of 148.19% in 2024 [9]. Impact on Investors - At least nine fund companies have been affected by the financial fraud, with some, including Huaxia Fund, newly entering as shareholders in the second quarter of 2025 [2][10].